Last reviewed · How we verify
TRK-100STP high dose
At a glance
| Generic name | TRK-100STP high dose |
|---|---|
| Sponsor | Toray Industries, Inc |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- TRK-100STP PhaseII Clinical Study -Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis) (PHASE2)
- TRK-100STP Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis) (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TRK-100STP high dose CI brief — competitive landscape report
- TRK-100STP high dose updates RSS · CI watch RSS
- Toray Industries, Inc portfolio CI